Efficacy
death, tumor, enlargement, SD, PD, adenocarcinoma
DISEASE PROGRESSION, SQUAMOUS CELL CARCINOMA, TUMOR, ENLARGEMENT, ADVERSE EVENTS, DISEASE, SOLID TUMORS, ADENOCARCINOMA, ONCOLOGY
Of the 29 assessable patients, 1 (3.4%) achieved complete response (CR), 15 (51.7%) had partial response (PR), 9 (31.0%) had stable disease (SD), and 4 (13.8%) experienced PD. The ORR was 55.2% (95% CI: 28.1%–79.6%) and the DCR was 86.2% (95% CI: 65.9%–97.0%), suggesting high efficacy (Table Treatment outcomes.Abbreviations: CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; PD‐L1, programmed death ligand 1; PFS, progression‐free survival.Waterfall plots for the best percentage change in target lesion size from the baseline are shown for all patients. The patterns of each bar indicate the best overall response assessed by the response evaluation criteria in solid tumors version 1.1.Kaplan–Meier estimates for progression‐free survival (A) and overall survival (B) of all patients.Although no statistically significant differences were observed, younger patients (<70 years) and those with PS 0, squamous cell carcinoma, and 1 previous regimen tended to have a good response, while patient populations with apparently low ORR (<40%) could not be identified (Table Treatment outcomes.Abbreviations: ECOG, Eastern Cooperative Oncology Group; ICI, immune‐checkpoint inhibitor; PD, progressive disease; PD‐L1, programmed death ligand 1; PR, partial response; SD, stable disease.Prognostic factors of nab‐paclitaxel therapy using Cox models.Abbreviations: CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; ICI, immune‐checkpoint inhibitor; NR, not reached; OS, overall survival; PD, progressive disease; PD‐L1, programmed death ligand 1; PFS, progression‐free survival; PR, partial response; PS, performance status; SD, stable disease; sq, squamous cell carcinoma.Kaplan–Meier estimates for progression‐free survival stratified by age (A), ECOG‐PS (B), and confirmed response to previous ICI therapy (C).Kaplan–Meier estimates for overall survival stratified by age (A), ECOG‐PS (B), and confirmed response to previous ICI therapy (C).Figure Representative CT images of a patient who showed long‐term response to nab‐paclitaxel after failure of pembrolizumab therapy. A 69‐year‐old man with an adenocarcinoma in his right upper lung lobe (A) received pembrolizumab monotherapy as a second‐line treatment. After 1 week of pembrolizumab therapy, a transient mild enlargement was observed (B), followed by a slight shrinkage 2 months later (C). However, disease progression was observed 3 months after the initiation of pembrolizumab therapy (D). He received nab‐paclitaxel immediately after pembrolizumab failure. Two months after nab‐paclitaxel monotherapy, considerable tumor shrinkage was observed (E). This response persisted until 3 years (F), with minimal adverse events, and the patients are still receiving nab‐paclitaxel therapy.